You are here: Industry Insights > Genmab

News List

Genmab Gains Broad Access to Synaffix's ADC Technologies contractpharma
January 04, 2022
Secures rights for conducting research on ADCs against multiple drug targets under new licensing agreement.
Genmab, Bolt ink deal to develop bispecific immune-stimulating antibody conjugates firstwordpharma
June 03, 2021
Genmab entered into an agreement with Bolt Biotherapeutics to develop next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer, the companies announced Wednesday.
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study pharmatimes
August 04, 2020
Genmab and Janssen’s subcutaneous formulation of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone (Pd) has generated positive results in a phase 3 myeloma trial.
AbbVie and Genmab link for oncology collaboration pharmatimes
June 16, 2020
AbbVie and Genmab have signed a pact to jointly develop and commercialise three of the latter's early-stage investigational bispecific antibody product candidates ...
AbbVie inks $750m cancer therapeutics deal with Genmab pharmaceutical-technology
June 15, 2020
AbbVie has entered a collaboration agreement with biotechnology company Genmab to develop and commercialise antibody therapeutics for cancer.
Abbvie, Genmab Enter $750M Antibody Alliance contractpharma
June 11, 2020
To jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates.
Genmab, CureVac Enter Partnership to Develop mRNA-based Antibody Therapeutics americanpharmaceuticalreview
December 23, 2019
Genmab and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus on the research and development of ...
Genmab, Janssen Partner for Next-Gen CD38 Antibody contractpharma
June 20, 2019
To collaborate on HexaBody-CD38, a next-generation CD38 antibody product incorporating Genmab's HexaBody technology.
Genmab and Janssen Biotech to develop CD38 antibody pharmaceutical-technology
June 14, 2019
Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).
Immatics, Genmab to develop bispecific cancer immunotherapies biospectrumasia
July 16, 2018
Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets

Previous page 1 2 Next page